Why Adaptive Biotechnologies and Smartsheet will be mega-cap stocks in the future.
News & Analysis: Adaptive Biotechnologies Corporation
ADPT earnings call for the period ending March 31, 2020.
Revenue skyrocketed in the first quarter. But so did Adaptive's spending.
The "ImmuneRace" study will genetically map the T-cells of 1,000 people who have been exposed to SARS-CoV-19.
One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.
In the midst of a global market meltdown, I'm buying virtual companies that are winning market share.
This biotech is seeking to understand the immune system to develop insights and drug products for the most vexing health problems, including COVID-19.
Adaptive Biotechnologies and Axsome Therapeutics are under-followed stocks with large upsides.
The two biotechs aren't wasting any time getting their new joint COVID-19 effort up and running.
The companies teamed up in early 2018 to try to map how the immune system responds to various diseases. Next on their agenda: SARS-CoV-2.